Evidence map›Paper›PMID 42166831›Full record

ReviewBreast (Edinburgh, Scotland)2026

Evolution of ER-cut-off definition in clinical trials for triple negative breast cancer: trends and patterns over 15 years.

Giorgio Bonomi, Davide Napetti, Gaia Griguolo, Francesca Zanghì, Fabio Girardi, Stefania Lando, Pietro Napolitano, Giusy Landa, Marina La Commare, Davide Massa and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Giorgio BonomiDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Davide NapettiDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Gaia GriguoloDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Electronic address: gaia.griguolo@unipd.it.
Francesca ZanghìDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Fabio GirardiDivision of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Stefania LandoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy; BIOSTAT-X Biostatistics and AI for Biomedical Discovery, Pediatric Research Institute (IRP), Città della Speranza, Padova, Italy; PhD Program in Translation Specialistic Medicine "G.B. Morgagni", Curriculum "Biostatistics and Clinical Epidemiology", University of Padova, Padova, Italy.
Pietro NapolitanoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Giusy LandaDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Marina La CommareDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Davide MassaDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Valentina GuarneriDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Maria Vittoria DieciDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is historically defined as oestrogen receptor (ER) < 1% and HER2-negative. Increasing evidence supports that ER-low breast cancer (BC) (ER 1-10%) shares similar clinical behaviour and biology with classic TNBC. However, how ER cut-off definitions have been applied as eligibility criteria in clinical trials for TNBC over time remains unclear. In August 2024, the Clinicaltrials.gov database was systematically queried using the following string: "breast cancer" AND "interventional studies" AND "phase II-III-not applicable". We included trials started from January, 1, 2010 to August, 7, 2024 restricted to TNBC, using either ER<1% or any other ER cut-off up to 10%. Differences across study descriptors were assessed using Mann-Whitney U and χ

Indexed as

Clinical Trials as TopicReceptors, EstrogenTriple Negative Breast NeoplasmsFemaleHumansReceptors, EstrogenBreast cancerClinical trialsER-lowTNBC

Identifiers

PMID42166831
PMCPMC13218251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.